NASDAQ:HOLX - Hologic Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $86.53
Forecasted Upside: 38.14 %
Number of Analysts: 14
Breakdown:
0 Sell Ratings
3 Hold Ratings
11 Buy Ratings
0 Strong Buy Ratings

^$62.64 As of 05/17/2021 01:00 AM ET

▼ -1.1 (-1.73%)

1 month | 3 months | 12 months

Get New Hologic Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HOLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOLX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$86.53

▲ +38.14% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $86.53, with a high forecast of $110.00 and a low forecast of $64.00. The average price target represents a 38.14% upside from the last price of $62.64.

Buy

The current consensus among 14 polled investment analysts is to buy stock in Hologic. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

11/24/2019

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/22/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

5/22/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

8/20/2020

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

11/18/2020

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/16/2021

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/17/2021

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/17/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/6/2021	Morgan Stanley	Lower Price Target	Equal Weight	$84.00 ➝ $77.00	Low	i
5/5/2021	SVB Leerink	Lower Price Target	Outperform	$94.00 ➝ $85.00	Low	i
5/5/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target	Buy	$90.00 ➝ $80.00	Low	i
4/30/2021	Morgan Stanley	Lower Price Target	Equal Weight	$84.00 ➝ $77.00	Medium	i
4/29/2021	Citigroup	Lower Price Target		$90.00 ➝ $80.00	Low	i
4/29/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target	Buy	$90.00 ➝ $80.00	High	i
4/29/2021	SVB Leerink	Lower Price Target	Outperform	$94.00 ➝ $85.00	High	i
4/5/2021	Jefferies Financial Group	Boost Price Target	Buy	$106.00 ➝ $110.00	Low	i
3/1/2021	Robert W. Baird	Boost Price Target	Buy	$84.00 ➝ $91.00	Low	i
2/22/2021	Robert W. Baird	Reiterated Rating	Buy	$84.00 ➝ $91.00	Low	i
2/22/2021	BTIG Research	Boost Price Target	Buy	$84.00 ➝ $91.00	Medium	i
1/28/2021	Wells Fargo & Company	Boost Price Target	Overweight	$90.00 ➝ $95.00	Medium	i
1/6/2021	Raymond James	Reiterated Rating	Buy		N/A	i
12/15/2020	Morgan Stanley	Boost Price Target	Equal Weight	$80.00 ➝ $84.00	Low	i
12/8/2020	Argus	Boost Price Target		$85.00 ➝ $100.00	Low	i
11/20/2020	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low	i Rating by Michael Matson at Needham & Company LLC
11/9/2020	Morgan Stanley	Boost Price Target	Equal Weight	$68.00 ➝ $80.00	High	i
11/5/2020	Jefferies Financial Group	Boost Price Target		$80.00 ➝ $98.00	Low	i
11/5/2020	Smith Barney Citigroup	Boost Price Target		$90.00 ➝ $85.00	Low	i
11/5/2020	UBS Group	Boost Price Target	Neutral	$77.00 ➝ $81.00	Low	i
11/5/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$75.00 ➝ $85.00	High	i
11/5/2020	Wells Fargo & Company	Boost Price Target	Overweight	$80.00 ➝ $90.00	High	i
11/5/2020	Raymond James	Boost Price Target	Outperform	$75.00 ➝ $86.00	Medium	i
11/5/2020	SVB Leerink	Boost Price Target	Outperform	$80.00 ➝ $94.00	Low	i
11/5/2020	Needham & Company LLC	Boost Price Target	Buy	$78.00 ➝ $88.00	Medium	i Rating by Michael Matson at Needham & Company LLC
8/26/2020	Needham & Company LLC	Reiterated Rating	Buy	$78.00	Low	i Rating by Michael Matson at Needham & Company LLC
7/31/2020	Morgan Stanley	Boost Price Target	Equal Weight	$55.00 ➝ $68.00	Low	i
7/30/2020	Wells Fargo & Company	Boost Price Target	Overweight	$63.00 ➝ $80.00	High	i
7/30/2020	Raymond James	Boost Price Target	Outperform	$68.00 ➝ $78.00	High	i
7/30/2020	Citigroup	Boost Price Target	Positive ➝ Buy	$63.00 ➝ $85.00	Low	i
7/30/2020	SVB Leerink	Boost Price Target	Outperform	$66.00 ➝ $80.00	Low	i Rating by R. Newitter at SVB Leerink LLC
7/30/2020	Needham & Company LLC	Boost Price Target	Buy	$64.00 ➝ $78.00	Low	i Rating by Michael Matson at Needham & Company LLC
7/29/2020	BTIG Research	Reiterated Rating	Buy	$63.00 ➝ $84.00	Low	i Rating by Ryan Zimmerman at BTIG Research
7/27/2020	William Blair	Reiterated Rating	Outperform		Low	i Rating by B. Weinstein at William Blair
7/23/2020	Raymond James	Boost Price Target	Outperform	$62.00 ➝ $68.00	Low	i
7/15/2020	SVB Leerink	Boost Price Target	Outperform	$62.00 ➝ $66.00	Low	i Rating by R. Newitter at SVB Leerink LLC
7/1/2020	Needham & Company LLC	Initiated Coverage	Buy	$60.00 ➝ $64.00	High	i Rating by Michael Matson at Needham & Company LLC
6/30/2020	Cowen	Upgrade	Market Perform ➝ Outperform	$64.00	High	i
6/26/2020	BTIG Research	Reiterated Rating	Buy	$60.00	Low	i Rating by Ryan Zimmerman at BTIG Research
6/16/2020	BTIG Research	Boost Price Target	Buy	$54.00 ➝ $60.00	Low	i
6/10/2020	Needham & Company LLC	Reiterated Rating	Buy		Low	i Rating by Michael Matson at Needham & Company LLC
6/9/2020	Morgan Stanley	Boost Price Target	Equal Weight	$53.00 ➝ $55.00	Low	i
6/3/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$62.00	Medium	i
6/2/2020	Needham & Company LLC	Initiated Coverage	Buy	$60.00	High	i Rating by Michael Matson at Needham & Company LLC
4/30/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$45.00 ➝ $55.00	High	i
4/30/2020	Morgan Stanley	Boost Price Target	Equal Weight	$40.00 ➝ $53.00	High	i
4/30/2020	Wells Fargo & Company	Boost Price Target	Overweight	$48.00 ➝ $60.00	High	i
4/30/2020	BTIG Research	Boost Price Target	Buy	$46.00 ➝ $54.00	High	i
4/30/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$41.00 ➝ $62.00	High	i Rating by Richard Newitter at SVB Leerink LLC
4/30/2020	Needham & Company LLC	Boost Price Target	Buy	$52.00 ➝ $60.00	High	i Rating by Michael Matson at Needham & Company LLC
4/28/2020	UBS Group	Lower Price Target	Neutral	$58.00 ➝ $52.00	Low	i
4/19/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight		Medium	i
4/8/2020	SVB Leerink	Lower Price Target	Market Perform	$57.00 ➝ $41.00	High	i Rating by Richard Newitter at SVB Leerink LLC
4/8/2020	Stifel Nicolaus	Lower Price Target	Hold	$52.00 ➝ $45.00	High	i
4/8/2020	William Blair	Reiterated Rating	Outperform		High	i Rating by Brian Weinstein at William Blair
4/7/2020	BTIG Research	Reiterated Rating	Positive ➝ Buy	$54.00 ➝ $46.00	Low	i
4/7/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$48.00	High	i
4/2/2020	Needham & Company LLC	Upgrade	Buy	$62.00 ➝ $52.00	High	i
3/27/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$53.00 ➝ $40.00	Low	i
3/26/2020	Barclays	Lower Price Target	Equal Weight	$51.00 ➝ $43.00	High	i
3/17/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$60.00 ➝ $50.00	High	i
1/30/2020	Piper Sandler	Boost Price Target		$58.00 ➝ $61.00	Low	i
1/30/2020	BTIG Research	Reiterated Rating	Buy	$54.00	Medium	i
1/13/2020	Barclays	Boost Price Target	Equal Weight	$50.00 ➝ $51.00	Low	i
1/13/2020	Needham & Company LLC	Boost Price Target	Buy	$57.00 ➝ $62.00	Low	i
1/7/2020	Wells Fargo & Company	Initiated Coverage	Equal Weight	$57.00	Low	i
1/6/2020	Citigroup	Initiated Coverage	Buy	$60.00	Low	i
1/2/2020	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight		Low	i
12/17/2019	Morgan Stanley	Boost Price Target	Underweight	$45.00 ➝ $50.00	Low	i
12/13/2019	Stifel Nicolaus	Boost Price Target	Hold	$48.00 ➝ $52.00	Low	i
11/21/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Brian Weinstein at William Blair
11/20/2019	SVB Leerink	Reiterated Rating	Hold	$50.00	Medium	i Rating by Richard Newitter at SVB Leerink LLC
9/26/2019	Bank of America	Upgrade	Neutral ➝ Buy	$54.00 ➝ $59.00	High	i
8/14/2019	Argus	Boost Price Target	Buy	$62.00	High	i
8/5/2019	Stifel Nicolaus	Boost Price Target	Hold	$43.00 ➝ $48.00	Medium	i
8/1/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$49.00 ➝ $59.00	Low	i
8/1/2019	Canaccord Genuity	Reiterated Rating	Hold	$52.00	Low	i
8/1/2019	BTIG Research	Reiterated Rating	Buy	$52.00	High	i
8/1/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $57.00	High	i
7/10/2019	Needham & Company LLC	Reiterated Rating	Buy	$52.00	Low	i
5/2/2019	BTIG Research	Reiterated Rating	Buy	$52.00	Low	i
5/2/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $52.00	Medium	i
4/2/2019	Needham & Company LLC	Reiterated Rating	Buy	$50.00	Low	i
1/31/2019	BTIG Research	Reiterated Rating	Buy	$50.00	High	i
1/31/2019	Piper Jaffray Companies	Boost Price Target	In-Line ➝ Overweight	$49.00	High	i
1/31/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $50.00	High	i
1/14/2019	Needham & Company LLC	Reiterated Rating	Buy	$48.00	Low	i
1/7/2019	Canaccord Genuity	Reiterated Rating	Hold	$41.00	High	i
1/4/2019	Cowen	Downgrade	Outperform ➝ Market Perform	$38.28	Medium	i
1/2/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$44.00 ➝ $39.00	High	i
11/30/2018	Royal Bank of Canada	Boost Price Target	Sector Perform ➝ Sector Perform	$40.00 ➝ $46.00	Low	i
11/8/2018	Canaccord Genuity	Reiterated Rating	Hold	$43.00	Low	i
11/8/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$45.00	N/A	i
10/11/2018	Morgan Stanley	Lower Price Target	Equal Weight	$47.00 ➝ $44.00	Medium	i
10/9/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$44.00	Medium	i
9/27/2018	Canaccord Genuity	Boost Price Target	Hold ➝ Hold	$40.00 ➝ $41.00	Low	i
9/27/2018	Needham & Company LLC	Reiterated Rating	Buy	$48.00	N/A	i
9/13/2018	Canaccord Genuity	Lower Price Target	Hold	$41.00 ➝ $40.00	Low	i
9/13/2018	Bank of America	Downgrade	Buy ➝ Neutral	$47.00 ➝ $42.00	High	i
9/5/2018	Barclays	Downgrade	Overweight ➝ Equal Weight	$50.00 ➝ $43.00	High	i
8/20/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold ➝ Hold	$45.00 ➝ $43.00	Low	i Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
8/14/2018	Canaccord Genuity	Lower Price Target	Hold ➝ Hold	$42.00 ➝ $41.00	Medium	i
8/13/2018	Needham & Company LLC	Reiterated Rating	Buy	$48.00	High	i
8/2/2018	BTIG Research	Reiterated Rating	Buy	$47.00	Medium	i
8/1/2018	Cowen	Reiterated Rating	Buy	$45.00	Medium	i
8/1/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$44.00 ➝ $47.00	Medium	i
8/1/2018	Jefferies Financial Group	Reiterated Rating	Buy	$50.00	Medium	i
8/1/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold ➝ Hold	$42.00 ➝ $45.00	High	i Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
8/1/2018	Needham & Company LLC	Boost Price Target	Buy	$43.00 ➝ $48.00	High	i
5/6/2018	BTIG Research	Reiterated Rating	Buy	$44.00	Medium	i
5/3/2018	Barclays	Lower Price Target	Overweight ➝ Overweight	$54.00 ➝ $50.00	High	i
5/3/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold ➝ Hold	$44.00 ➝ $42.00	High	i Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
5/3/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$42.00 ➝ $40.00	High	i
5/3/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$48.00 ➝ $41.00	High	i Rating by R. Newitter at SVB Leerink LLC
5/3/2018	Canaccord Genuity	Downgrade	Buy ➝ Hold	$48.00 ➝ $39.00	High	i
5/1/2018	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $43.00	Low	i
4/17/2018	The Goldman Sachs Group	Set Price Target	Buy	$43.00	Low	i Rating by Isaac Ro at The Goldman Sachs Group, Inc.
3/26/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy	$43.00	Low	i
2/9/2018	Canaccord Genuity	Reiterated Rating	Buy	$48.00	Low	i
2/9/2018	Royal Bank of Canada	Reiterated Rating	Hold	$44.00	High	i
2/9/2018	Needham & Company LLC	Reiterated Rating	Buy	$50.00	High	i
2/9/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$45.00 ➝ $42.00	High	i
2/1/2018	Needham & Company LLC	Reiterated Rating	Buy	$50.00	Low	i
1/19/2018	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$49.00	Medium	i
1/9/2018	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $50.00	Low	i
1/4/2018	Bank of America	Upgrade	Neutral ➝ Buy	$50.00	Low	i Rating by Derik De Bruin at Bank of America Co.
1/3/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$50.00	Medium	i
12/20/2017	Cowen	Upgrade	Buy	$52.00	Low	i
12/11/2017	Cowen	Upgrade	Market Perform ➝ Outperform	$51.00	High	i
12/8/2017	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$45.00 ➝ $50.00	Low	i Rating by Isaac Ro at The Goldman Sachs Group, Inc.
12/5/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $48.00	Low	i
11/9/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$48.00	N/A	i
11/3/2017	Needham & Company LLC	Reiterated Rating	Buy	$50.00	N/A	i
10/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$49.00 ➝ $44.00	N/A	i Rating by Steven Desanctis at Jefferies Financial Group Inc.
10/9/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $45.00	N/A	i
10/2/2017	Needham & Company LLC	Reiterated Rating	Buy	$50.00	Medium	i
9/22/2017	Royal Bank of Canada	Reiterated Rating	Hold	$42.00	Low	i
8/9/2017	Barclays	Reiterated Rating	Equal Weight	$53.00 ➝ $51.00	Low	i Rating by Jack Meehan at Barclays PLC
8/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$50.00 ➝ $45.00	Low	i
8/3/2017	Barclays	Lower Price Target	Overweight	$53.00 ➝ $51.00	Medium	i Rating by Jack Meehan at Barclays PLC
8/3/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$51.00 ➝ $49.00	Medium	i
8/3/2017	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy	$48.00 ➝ $47.00	High	i
8/3/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$50.00 ➝ $45.00	High	i
8/1/2017	Needham & Company LLC	Reiterated Rating	Buy		Medium	i
7/21/2017	Bank of America	Reiterated Rating	Neutral	$44.00 ➝ $48.00	Low	i
7/17/2017	Barclays	Reiterated Rating	Overweight	$50.00 ➝ $53.00	Low	i Rating by Jack Meehan at Barclays PLC
7/14/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$51.00	Medium	i
7/14/2017	Stifel Nicolaus	Reiterated Rating	Buy		Medium	i
6/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$49.00	Low	i Rating by Steven Desanctis at Jefferies Financial Group Inc.
5/28/2017	Jefferies Financial Group	Set Price Target	Buy	$49.00	Low	i Rating by Steven Desanctis at Jefferies Financial Group Inc.
5/14/2017	BTIG Research	Reiterated Rating	Buy	$47.00	Low	i
5/11/2017	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $48.00	High	i
5/9/2017	Canaccord Genuity	Reiterated Rating	Buy	$53.00	Low	i Rating by Mark Massaro at Canaccord Genuity
4/5/2017	Barclays	Set Price Target	Buy	$50.00	Low	i Rating by Jack Meehan at Barclays PLC
4/4/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $50.00	Medium	i
3/30/2017	SVB Leerink	Reiterated Rating	Outperform	$52.00	Low	i Rating by R. Newitter at SVB Leerink LLC
3/14/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$51.00	Low	i
3/13/2017	Jefferies Financial Group	Reiterated Rating	Buy	$46.00 ➝ $49.00	Low	i
2/15/2017	Needham & Company LLC	Upgrade	Hold ➝ Buy	$46.00	N/A	i
2/15/2017	Bank of America	Downgrade	Buy ➝ Neutral		N/A	i
2/5/2017	BTIG Research	Reiterated Rating	Buy	$47.00	N/A	i
1/23/2017	Canaccord Genuity	Set Price Target	Buy	$48.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
1/18/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$48.00	N/A	i
1/8/2017	Jefferies Financial Group	Reiterated Rating	Buy	$46.00	N/A	i
1/4/2017	Evercore ISI	Downgrade	Buy ➝ Hold	$42.00	N/A	i
1/4/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$44.00 ➝ $48.00	N/A	i Rating by william quirk at Piper Jaffray Companies
12/16/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
12/15/2016	Canaccord Genuity	Set Price Target	Buy	$48.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
11/19/2016	Barclays	Set Price Target	Buy	$45.00	N/A	i Rating by Jack Meehan at Barclays PLC
11/3/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
11/3/2016	BTIG Research	Boost Price Target	Buy	$44.00 ➝ $47.00	N/A	i
11/3/2016	Barclays	Reiterated Rating	Buy	$45.00	N/A	i Rating by jack meehan at Barclays PLC
11/3/2016	SVB Leerink	Reiterated Rating	Top Pick	$46.00 ➝ $43.00	N/A	i
10/15/2016	Evercore ISI	Reiterated Rating	Buy	$43.00	N/A	i
10/3/2016	SVB Leerink	Reiterated Rating	Outperform	$46.00	N/A	i Rating by Richard Newitter at SVB Leerink LLC
9/23/2016	Barclays	Upgrade	Equal Weight ➝ Overweight	$42.00 ➝ $44.00	N/A	i Rating by Jack Meehan at Barclays PLC
8/28/2016	Piper Jaffray Companies	Set Price Target	Hold	$44.00	N/A	i Rating by william quirk at Piper Jaffray Companies
8/1/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$37.00 ➝ $39.00	N/A	i
8/1/2016	Royal Bank of Canada	Boost Price Target	Sector Perform	$37.00 ➝ $39.00	N/A	i
7/31/2016	Barclays	Reiterated Rating	Equal Weight	$42.00	N/A	i Rating by Jack Meehan at Barclays PLC
7/28/2016	Canaccord Genuity	Set Price Target	Buy	$45.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
7/28/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i Rating by Michael Matson at Needham & Company LLC
7/28/2016	BTIG Research	Reiterated Rating	Buy	$44.00	N/A	i
7/28/2016	SVB Leerink	Reiterated Rating	Buy	$46.00	N/A	i Rating by Richard Newitter at SVB Leerink LLC
7/28/2016	Morgan Stanley	Boost Price Target	Equal Weight	$38.00 ➝ $40.00	N/A	i Rating by David Lewis at Morgan Stanley
7/28/2016	Jefferies Financial Group	Boost Price Target	Buy	$42.00 ➝ $43.00	N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
7/28/2016	Evercore ISI	Upgrade	Hold ➝ Buy	$38.00 ➝ $42.00	N/A	i
7/25/2016	Piper Jaffray Companies	Set Price Target	Hold	$40.00	N/A	i Rating by William Quirk at Piper Jaffray Companies
7/17/2016	UBS Group	Reiterated Rating	Buy	$45.00	N/A	i Rating by Jon Groberg at UBS Group AG
7/10/2016	Barclays	Reiterated Rating	Hold	$42.00	N/A	i
6/22/2016	Bank of America	Reiterated Rating	Buy		N/A	i Rating by Derik De Bruin at Bank of America Co.
6/21/2016	Jefferies Financial Group	Reiterated Rating	Buy	$42.00	N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
6/6/2016	UBS Group	Reiterated Rating	Buy	$45.00	N/A	i Rating by Jon Groberg at UBS Group AG
6/4/2016	Morgan Stanley	Reiterated Rating	Hold		N/A	i Rating by David Lewis at Morgan Stanley

(Data available from 5/18/2016 forward)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $62.64

$62.57

$64.16

50 Day Range

MA: $70.98

$62.80

$76.68

52 Week Range

Now: $62.64

$49.19

$85.00

Volume

2,211,025 shs

Average Volume

2,156,254 shs

Market Capitalization

$16.05 billion

P/E Ratio

14.91

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Hologic?

The following Wall Street research analysts have issued reports on Hologic in the last year: Argus, BTIG Research, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Smith Barney Citigroup, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for HOLX.

What is the current price target for Hologic?

15 Wall Street analysts have set twelve-month price targets for Hologic in the last year. Their average twelve-month price target is $86.53, suggesting a possible upside of 38.1%. Jefferies Financial Group Inc. has the highest price target set, predicting HOLX will reach $110.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $64.00 for Hologic in the next year.
View the latest price targets for HOLX.

What is the current consensus analyst rating for Hologic?

Hologic currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOLX will outperform the market and that investors should add to their positions of Hologic.
View the latest ratings for HOLX.

What other companies compete with Hologic?

Other companies that are similar to Hologic include Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, Becton, Dickinson and, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Baxter International, DexCom, ResMed, Teleflex, STERIS, Insulet and Abiomed.

How do I contact Hologic's investor relations team?

Hologic's physical mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is 508-263-2900 and its investor relations email address is [email protected] The official website for Hologic is www.hologic.com.